S&P 500   3,263.62 (-1.68%)
DOW   27,039.41 (-2.23%)
QQQ   264.77 (-0.79%)
AAPL   107.97 (+1.06%)
MSFT   200.63 (+0.12%)
FB   247.39 (-2.04%)
GOOGL   1,425.05 (-1.79%)
AMZN   2,904.13 (-1.72%)
NVDA   493.38 (+1.19%)
TSLA   444.26 (+0.48%)
BABA   271.90 (-0.19%)
CGC   15.64 (-4.40%)
GE   6.30 (-8.43%)
MU   48.89 (-3.65%)
AMD   76.87 (+2.59%)
T   28.45 (-1.66%)
F   6.88 (-4.84%)
ACB   6.32 (-3.22%)
GILD   63.63 (-2.18%)
NFLX   481.55 (+2.47%)
DIS   124.57 (-3.16%)
BAC   24.25 (-3.81%)
BA   156.95 (-2.60%)
S&P 500   3,263.62 (-1.68%)
DOW   27,039.41 (-2.23%)
QQQ   264.77 (-0.79%)
AAPL   107.97 (+1.06%)
MSFT   200.63 (+0.12%)
FB   247.39 (-2.04%)
GOOGL   1,425.05 (-1.79%)
AMZN   2,904.13 (-1.72%)
NVDA   493.38 (+1.19%)
TSLA   444.26 (+0.48%)
BABA   271.90 (-0.19%)
CGC   15.64 (-4.40%)
GE   6.30 (-8.43%)
MU   48.89 (-3.65%)
AMD   76.87 (+2.59%)
T   28.45 (-1.66%)
F   6.88 (-4.84%)
ACB   6.32 (-3.22%)
GILD   63.63 (-2.18%)
NFLX   481.55 (+2.47%)
DIS   124.57 (-3.16%)
BAC   24.25 (-3.81%)
BA   156.95 (-2.60%)
S&P 500   3,263.62 (-1.68%)
DOW   27,039.41 (-2.23%)
QQQ   264.77 (-0.79%)
AAPL   107.97 (+1.06%)
MSFT   200.63 (+0.12%)
FB   247.39 (-2.04%)
GOOGL   1,425.05 (-1.79%)
AMZN   2,904.13 (-1.72%)
NVDA   493.38 (+1.19%)
TSLA   444.26 (+0.48%)
BABA   271.90 (-0.19%)
CGC   15.64 (-4.40%)
GE   6.30 (-8.43%)
MU   48.89 (-3.65%)
AMD   76.87 (+2.59%)
T   28.45 (-1.66%)
F   6.88 (-4.84%)
ACB   6.32 (-3.22%)
GILD   63.63 (-2.18%)
NFLX   481.55 (+2.47%)
DIS   124.57 (-3.16%)
BAC   24.25 (-3.81%)
BA   156.95 (-2.60%)
S&P 500   3,263.62 (-1.68%)
DOW   27,039.41 (-2.23%)
QQQ   264.77 (-0.79%)
AAPL   107.97 (+1.06%)
MSFT   200.63 (+0.12%)
FB   247.39 (-2.04%)
GOOGL   1,425.05 (-1.79%)
AMZN   2,904.13 (-1.72%)
NVDA   493.38 (+1.19%)
TSLA   444.26 (+0.48%)
BABA   271.90 (-0.19%)
CGC   15.64 (-4.40%)
GE   6.30 (-8.43%)
MU   48.89 (-3.65%)
AMD   76.87 (+2.59%)
T   28.45 (-1.66%)
F   6.88 (-4.84%)
ACB   6.32 (-3.22%)
GILD   63.63 (-2.18%)
NFLX   481.55 (+2.47%)
DIS   124.57 (-3.16%)
BAC   24.25 (-3.81%)
BA   156.95 (-2.60%)
Log in
NASDAQ:ONTX

Onconova Therapeutics Stock Forecast, Price & News

$0.36
+0.04 (+11.87 %)
(As of 09/21/2020 03:15 PM ET)
Add
Compare
Today's Range
$0.35
Now: $0.36
$0.44
50-Day Range
$0.21
MA: $0.66
$1.18
52-Week Range
$0.10
Now: $0.36
$1.86
Volume2.36 million shs
Average Volume16.33 million shs
Market Capitalization$64.68 million
P/E RatioN/A
Dividend YieldN/A
Beta2.07
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Read More
Onconova Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.27 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONTX
CUSIPN/A
Phone267-759-3680

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.18 million
Book Value$0.08 per share

Profitability

Net Income$-21,500,000.00
Net Margins-11,357.71%

Miscellaneous

Employees25
Market Cap$64.68 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$0.36
+0.04 (+11.87 %)
(As of 09/21/2020 03:15 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ONTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions

How has Onconova Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Onconova Therapeutics' stock was trading at $0.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ONTX shares have increased by 2.3% and is now trading at $0.3684.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Onconova Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Onconova Therapeutics
.

When is Onconova Therapeutics' next earnings date?

Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Onconova Therapeutics
.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics Inc (NASDAQ:ONTX) released its earnings results on Wednesday, August, 12th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.01. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.40 million. Onconova Therapeutics had a negative net margin of 11,357.71% and a negative return on equity of 214.79%.
View Onconova Therapeutics' earnings history
.

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Shares of Onconova Therapeutics reverse split on Wednesday, September 26th 2018. The 1-15 reverse split was announced on Tuesday, September 25th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 25th 2018. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for ONTX?

4 brokerages have issued 1-year price targets for Onconova Therapeutics' stock. Their forecasts range from $1.25 to $2.00. On average, they expect Onconova Therapeutics' share price to reach $1.52 in the next twelve months. This suggests a possible upside of 311.7% from the stock's current price.
View analysts' price targets for Onconova Therapeutics
.

Who are some of Onconova Therapeutics' key competitors?

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), Opko Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Actinium Pharmaceuticals (ATNM), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Outlook Therapeutics (OTLK) and Acasti Pharma (ACST).

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the following people:
  • Dr. Steven M. Fruchtman, CEO, Pres & Director (Age 68)
  • Dr. E. Premkumar Reddy, Founder, Lead Scientific Advisor & Director (Age 75)
  • Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 56)
  • Dr. Ramesh Kumar, Advisor (Age 63)
  • Mr. Mark Patrick Guerin, Chief Financial Officer (Age 50)

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Captrust Financial Advisors (0.06%), FNY Investment Advisers LLC (0.06%) and Jane Street Group LLC (0.03%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin, Steven M Fruchtman and Tyndall Capital Partners L P.
View institutional ownership trends for Onconova Therapeutics
.

Which institutional investors are buying Onconova Therapeutics stock?

ONTX stock was purchased by a variety of institutional investors in the last quarter, including Captrust Financial Advisors, FNY Investment Advisers LLC, and Jane Street Group LLC. Company insiders that have bought Onconova Therapeutics stock in the last two years include Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin, and Steven M Fruchtman.
View insider buying and selling activity for Onconova Therapeutics
.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $0.37.

How big of a company is Onconova Therapeutics?

Onconova Therapeutics has a market capitalization of $66.18 million and generates $2.18 million in revenue each year. The biopharmaceutical company earns $-21,500,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.

What is Onconova Therapeutics' official website?

The official website for Onconova Therapeutics is www.onconova.com.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.